These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 38635853)

  • 1. Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody.
    Phan T; Zitzmann C; Chew KW; Smith DM; Daar ES; Wohl DA; Eron JJ; Currier JS; Hughes MD; Choudhary MC; Deo R; Li JZ; Ribeiro RM; Ke R; Perelson AS;
    PLoS Pathog; 2024 Apr; 20(4):e1011680. PubMed ID: 38635853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody.
    Phan T; Zitzmann C; Chew KW; Smith DM; Daar ES; Wohl DA; Eron JJ; Currier JS; Hughes MD; Choudhary MC; Deo R; Li JZ; Ribeiro RM; Ke R; Perelson AS;
    bioRxiv; 2023 Sep; ():. PubMed ID: 37745410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2.
    Choudhary MC; Deo R; Evering TH; Chew KW; Giganti MJ; Moser C; Ritz J; Regan J; Flynn JP; Crain CR; Wohl DA; Currier JS; Eron JJ; Margolis D; Zhu Q; Zhon L; Ya L; Greninger AL; Hughes MD; Smith D; Daar ES; Li JZ
    J Infect Dis; 2024 Aug; 230(2):394-402. PubMed ID: 38716969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
    Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
    MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evaluation of risk factors for prolonged viral shedding during anti-SARS-CoV-2 monoclonal antibodies and long-term administration of antivirals in COVID-19 patients with B-cell lymphoma treated by anti-CD20 antibody.
    Maruyama S; Wada D; Kanayama S; Shimazu H; Miyano Y; Inoue A; Kashihara M; Okuda K; Saito F; Nakamori Y; Ishii K; Kuwagata Y
    BMC Infect Dis; 2024 Jul; 24(1):715. PubMed ID: 39039440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.
    Zhang L; Poorbaugh J; Dougan M; Chen P; Gottlieb RL; Huhn G; Beasley S; Daniels M; Ngoc Vy Trinh T; Crisp M; Freitas JJ; Vaillancourt P; Patel DR; Nirula A; Kallewaard NL; Higgs RE; Benschop RJ
    Front Immunol; 2021; 12():790469. PubMed ID: 34956222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains.
    Chen RE; Winkler ES; Case JB; Aziati ID; Bricker TL; Joshi A; Darling TL; Ying B; Errico JM; Shrihari S; VanBlargan LA; Xie X; Gilchuk P; Zost SJ; Droit L; Liu Z; Stumpf S; Wang D; Handley SA; Stine WB; Shi PY; Davis-Gardner ME; Suthar MS; Knight MG; Andino R; Chiu CY; Ellebedy AH; Fremont DH; Whelan SPJ; Crowe JE; Purcell L; Corti D; Boon ACM; Diamond MS
    Nature; 2021 Aug; 596(7870):103-108. PubMed ID: 34153975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tackling COVID-19 with neutralizing monoclonal antibodies.
    Corti D; Purcell LA; Snell G; Veesler D
    Cell; 2021 Jun; 184(12):3086-3108. PubMed ID: 34087172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on the anti-spike monoclonal antibody pipeline for SARS-CoV-2.
    Focosi D; Franchini M; Casadevall A; Maggi F
    Clin Microbiol Infect; 2024 Aug; 30(8):999-1006. PubMed ID: 38663655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants.
    Oladunni FS; Park JG; Chiem K; Ye C; Pipenbrink M; Walter MR; Kobie J; Martinez-Sobrido L
    J Virol Methods; 2021 Apr; 290():114084. PubMed ID: 33513380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case.
    Tatham L; Kipar A; Sharp J; Kijak E; Herriott J; Neary M; Box H; Gallardo Toledo E; Valentijn A; Cox H; Pertinez H; Curley P; Arshad U; Rajoli RKR; Rannard S; Stewart JP; Owen A
    Microbiol Spectr; 2024 Aug; 12(8):e0391623. PubMed ID: 39012120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic barrier to resistance: a critical parameter for efficacy of neutralizing monoclonal antibodies against SARS-CoV-2 in a nonhuman primate model.
    Stahl-Hennig C; Peter AS; Cordsmeier A; Stolte-Leeb N; Vestweber R; Socher E; Merida SA; Sauermann U; Bleyer M; Fraedrich K; Grunwald T; Winkler TH; Ensser A; Jäck H-M; Überla K
    J Virol; 2024 Jul; 98(7):e0062824. PubMed ID: 38899895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies.
    Vellas C; Del Bello A; Debard A; Steinmeyer Z; Tribaudeau L; Ranger N; Jeanne N; Martin-Blondel G; Delobel P; Kamar N; Izopet J
    Clin Microbiol Infect; 2022 Jan; 28(1):139.e5-139.e8. PubMed ID: 34537363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 evolution during treatment of chronic infection.
    Kemp SA; Collier DA; Datir RP; Ferreira IATM; Gayed S; Jahun A; Hosmillo M; Rees-Spear C; Mlcochova P; Lumb IU; Roberts DJ; Chandra A; Temperton N; ; ; Sharrocks K; Blane E; Modis Y; Leigh KE; Briggs JAG; van Gils MJ; Smith KGC; Bradley JR; Smith C; Doffinger R; Ceron-Gutierrez L; Barcenas-Morales G; Pollock DD; Goldstein RA; Smielewska A; Skittrall JP; Gouliouris T; Goodfellow IG; Gkrania-Klotsas E; Illingworth CJR; McCoy LE; Gupta RK
    Nature; 2021 Apr; 592(7853):277-282. PubMed ID: 33545711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19.
    Kaku Y; Kuwata T; Zahid HM; Hashiguchi T; Noda T; Kuramoto N; Biswas S; Matsumoto K; Shimizu M; Kawanami Y; Shimura K; Onishi C; Muramoto Y; Suzuki T; Sasaki J; Nagasaki Y; Minami R; Motozono C; Toyoda M; Takahashi H; Kishi H; Fujii K; Tatsuke T; Ikeda T; Maeda Y; Ueno T; Koyanagi Y; Iwagoe H; Matsushita S
    Cell Rep; 2021 Jul; 36(2):109385. PubMed ID: 34237284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody drugs targeting SARS-CoV-2: Time for a rethink?
    Liang L; Wang B; Zhang Q; Zhang S; Zhang S
    Biomed Pharmacother; 2024 Jul; 176():116900. PubMed ID: 38861858
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.